In M. ulcerans S1013 cultures, Selamectin required AUC/MIC ratios between 10 and 15 for a bactericidal effect corresponding to 99.99% killing. In M. ulcerans S1012, Selamectin yielded an MIC of 2 μg/mL. Selamectin inhibited purified Mycobacterium smegmatis DprE1 recombinant enzyme with an IC50 of 2.6 ± 1.1 µM. For L282F M. smegmatis DprE1, the Selamectin IC50 was 1.0 ± 0.7 µM. [1,2]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Bactericidal activity in M. ulcerans cultures
Cell-based study · M. ulcerans S1013 [1]
M. ulcerans S1013 cultures were exposed to Selamectin, with colony-forming units measured after incubation. AUC/MIC ratios between 10 and 15 were required to achieve 99.99% killing.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0.5, 2, 4, 8, 16 and 32 μg/mL
- Exposure duration
- 0, 3, 7, 14 and 21 days
- Method
- Cultures were grown at 30°C in the presence of
- Reported limits
- Not stated in the sentences used: vehicle, control.
Methods and source locations
Compound reported in the paper: Selamectin
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and Methods > M. ulcerans kill-kinetic assay (S11, S12, S14); Results > Selamectin kills M. ulcerans (S26)
Colony-forming units for all plates were determined after 8 weeks of incubation at 30°C.: Colony-forming units for all plates were determined after 8 weeks of incubation at 30°C. — Materials and Methods > M. ulcerans kill-kinetic assay (S14); Results > Selamectin kills M. ulcerans (S26)
Inhibition of purified mycobacterial enzyme activity
Biochemical assay · purified Mycobacterium smegmatis DprE1 recombinant enzyme [2]
Purified Mycobacterium smegmatis DprE1 recombinant enzyme was incubated with Selamectin in a reaction mixture. Enzyme activity measured using the Amplex Red/peroxidase coupled assay yielded an IC50 of 2.6 ± 1.1 µM.
Literature-Reported Treatment Conditions
- Method
- incubated in a reaction mixture
- Reported limits
- Not stated in the sentences used: dose, schedule, vehicle.
Methods and source locations
Compound reported in the paper: Selamectin
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
2. Results > 2.2. Avermectins Inhibit the DprE1 Enzyme In Vitro (S11, S12); 4. Materials and Methods > 4.5. DprE1 Enzymatic Studies (S75, S76, S81); Table 2 (T2.r4); Table 3 (T3.r1)
Enzyme activity was determined with the Amplex Red/peroxidase coupled assay: Enzyme activity was determined with the Amplex Red/peroxidase coupled assay; comparator: enzyme activity in the absence of inhibitors — 2. Results > 2.2. Avermectins Inhibit the DprE1 Enzyme In Vitro (S12); 4. Materials and Methods > 4.5. DprE1 Enzymatic Studies (S75); Table 3 (T3.r1)
Growth inhibition in M. ulcerans cultures
Cell-based study · M. ulcerans strains S1012 [1]
M. ulcerans strains S1012 were incubated with Selamectin and assessed using a color-conversion readout. The reported MIC was 2 μg/mL.
Literature-Reported Treatment Conditions
- Exposure duration
- at 30°C for 8 days before addition of 20 μL of a resazurin solution (0.125 mg/mL), followed by overnight incubation at 37°C
- Method
- incubated in the presence of the drug
- Reported limits
- Not stated in the sentences used: dose, vehicle, control.
Methods and source locations
Compound reported in the paper: Selamectin
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and Methods > Bacterial strains, general growth conditions and reagents (S2); Materials and Methods > Drug susceptibility assays (S5, S8, S10); Table 1 (T1.h1, T1.h2, T1.r1)
The lowest concentration of drug that inhibited 90% of the MTT or resazurin color conversion (IC90) was used to define MIC values.: The lowest concentration of drug that inhibited 90% of the MTT or resazurin color conversion (IC90) was used to define MIC values. — Materials and Methods > Drug susceptibility assays (S10); Table 1 (T1.h1, T1.h2, T1.r1)
Enzyme inhibition in a mycobacterial variant
Cell-based study · L282F M. smegmatis DprE1 [2]
L282F M. smegmatis DprE1 was incubated with Selamectin in a reaction mixture. The measured IC50 was 1.0 ± 0.7 µM.
Literature-Reported Treatment Conditions
- Method
- incubated in a reaction mixture
- Reported limits
- Not stated in the sentences used: dose, schedule, vehicle.
Methods and source locations
Compound reported in the paper: Selamectin
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
4. Materials and Methods > 4.5. DprE1 Enzymatic Studies (S76, S81); Figure 4 legend (S110); Table 3 (T3.h1, T3.r5)
IC50 determination of selamectin: IC50 determination of selamectin; comparator: enzyme activity in the absence of inhibitors — Figure 4 legend (S110); Table 3 (T3.h1, T3.r5)